Immune Mediated Inflammatory Disease Forum

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the Phase 3 POETYK trials

Lebwohl M,

Warren RB,

Sofen H,

Imafuku S,

Paul C,

Szepietowski JC,

Spelman L,

Passeron T,

Vritzali E,

Napoli A,

Kisa RM,

Buck A,

Banerjee S,

Thaçi D,

Blauvelt A

Br J Dermatol 2024. doi: 10.1093/bjd/ljae014. Epub ahead of print

Researchers reported the safety and efficacy of deucravacitinib over 2 years in patients with chronic plaque PsO. The most frequently reported AEs were nasopharyngitis, URTI, and COVID-19.

Long-term deucravacitinib treatment maintained or improved efficacy across multiple measures.

Keywords:

Deucravacitinib,
Efficacy,
Phase 3,
Safety,
Skin,
TYK2

Publications

Keywords: